Our partners

English

Setting up drug discovery partnerships aimed at delivering clinical candidates is core to Inventiva’s strategy. These can be based on our internal programs as well as on our partners’ proprietary targets.

Abbvie Collaboration

Abbvie

We have entered into a multi-year drug discovery collaboration with Abbvie, in the context of which Inventiva leverages its discovery expertise and technology platforms to:

  • Deliver an IND-ready drug development candidate on an undisclosed program
  • Validate and provide leads in a series of targets of interest to our partner

This collaboration entitles Inventiva to receive research fees, milestones and sales royalties

Boehringer Ingelheim Collaboration

 

We have entered into a multi-year drug discovery collaboration with Boehringer Ingelheim to jointly validate a new therapeutic concept with the aim of discovering novel therapeutic molecules for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases.

This collaboration entitles Inventiva to receive research fees, milestones and sales royalties

Press-realease

Institut Curie Collaboration

Institut Curie

In September 2014, we have teamed up with Institut Curie to launch the Epicure project, with the financial support of France’s national research agency, the ANR (Agence Nationale pour la Recherche). The Epicure project focuses on two novel epigenetic targets implicated in immunomodulation. Epicure aims to confirm their therapeutic potential for the treatment of cancers such as breast cancer, ovarian cancer and melanoma, as well as some respiratory diseases. It also aims to identify molecules that are capable of regulating the activity of the targets and are therefore likely to become active drugs for the treatment of these diseases. The funding provided by the ANR covers a period of four years.

Press-release